Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease

Abstract

Peyronie’s disease treatments is changing again due the interruption of Xiapex® distrubution in Europe. There are many reasons that can be referred to this event. In this editorial we would like to shed light on the current cost items relating to treatment with collagenase clostridium histolyticum (CCH). The inaccessibility of the drug has seen both an increase in surgery for the treatments of both PD and Dupuytren’s disease and an interruption of therapies in patients who had not completed their therapeutic cycle. Considering the aforementioned concerns, we would like to invite researchers dealing with PD to conduct studies with the available CCH products in collaboration with the drug companies in order to give again an efficacious treatment for PD.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Rohit A, Peter A, Paul A, Anja B, Christian D, Renate D, et al. Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register. Arch Orthop Trauma Surg. 2019;139:1315–21.

    Article  Google Scholar 

  2. 2.

    Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    CAS  Article  Google Scholar 

  3. 3.

    Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction. Eur Urol. 2021. https://doi.org/10.1016/j.eururo.2021.06.007.

  4. 4.

    Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J Sex Med. 2019;16:1421–32.

    Article  Google Scholar 

  5. 5.

    Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: a systematic review of the literature. Eur Urol. 2018;74:767–81.

    Article  Google Scholar 

  6. 6.

    Cocci A, Russo GI, Briganti A, Salonia A, Cacciamani G, Capece M, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018;122:680–7.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

The corresponding author confirm that he had full access to the data in the study and final responsibility for the decision to submit for publication. Study concept and design: AC and GIR. Acquisition of data: none. Analysis and interpretation of data: none. Drafting of the manuscript: AC and GIR. Critical revision of the manuscript for important intellectual content: JIMS, DR, RPD, ECS, NM, AC, GIR. Statistical analysis: none. Obtaining funding: none. Administrative, technical, or material support: none. Supervision: AC and GIR.

Corresponding author

Correspondence to Giorgio Ivan Russo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cocci, A., Russo, G.I., Martinez-Salamanca, J.I. et al. Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease. Int J Impot Res (2021). https://doi.org/10.1038/s41443-021-00469-w

Download citation

Search

Quick links